We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Denali Therapeutics Inc. (DNLI - Free Report) shares soared 5.8% in the last trading session to close at $32.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% gain over the past four weeks.
Investors are upbeat about the company’s recent pipeline progress. The company will receive a milestone payment of $25 million from partner Sanofi which has commenced dosing in a mid-stage study of SAR443820 (DNL788) in individuals with multiple sclerosis. Other candidates are progressing well too.
This company is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -24.2%. Revenues are expected to be $8.03 million, down 35.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Denali Therapeutics Inc., the consensus EPS estimate for the quarter has been revised 1.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DNLI going forward to see if this recent jump can turn into more strength down the road.
Denali Therapeutics Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Prometheus Biosciences, Inc. , finished the last trading session 1.1% lower at $108.43. RXDX has returned 5.8% over the past month.
For Prometheus Biosciences, Inc., the consensus EPS estimate for the upcoming report has changed -7.7% over the past month to -$0.92. This represents a change of -19.5% from what the company reported a year ago. Prometheus Biosciences, Inc. currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
Denali Therapeutics Inc. (DNLI - Free Report) shares soared 5.8% in the last trading session to close at $32.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% gain over the past four weeks.
Investors are upbeat about the company’s recent pipeline progress. The company will receive a milestone payment of $25 million from partner Sanofi which has commenced dosing in a mid-stage study of SAR443820 (DNL788) in individuals with multiple sclerosis. Other candidates are progressing well too.
This company is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -24.2%. Revenues are expected to be $8.03 million, down 35.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Denali Therapeutics Inc., the consensus EPS estimate for the quarter has been revised 1.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DNLI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Denali Therapeutics Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Prometheus Biosciences, Inc. , finished the last trading session 1.1% lower at $108.43. RXDX has returned 5.8% over the past month.
For Prometheus Biosciences, Inc., the consensus EPS estimate for the upcoming report has changed -7.7% over the past month to -$0.92. This represents a change of -19.5% from what the company reported a year ago. Prometheus Biosciences, Inc. currently has a Zacks Rank of #2 (Buy).